Pathfinder Wealth Consulting’s AbbVie ABBV Stock Holding History

Pathfinder Wealth Consulting’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,710	Closed	-$807K	–	2
2026 Q1	$807K	Sell	3,710 -482	-11%	-$107K	0.52%	47
2025 Q4	$958K	Buy	+4,192	New	+$955K	0.6%	39

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Pathfinder Wealth Consulting's ABBV Position: Q2 2026 in Review

Pathfinder Wealth Consulting sold out of AbbVie (ABBV) in Q2 2026, closing a stake of 3,710 shares — an estimated $807K sold.

Pathfinder Wealth Consulting first reported a position in ABBV in Q4 2025 and held it in 2 quarters. The position peaked at $958K in Q4 2025. 4,207 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Pathfinder Wealth Consulting reported no remaining AbbVie position as of Q2 2026 after selling out during the quarter.
Pathfinder Wealth Consulting sold 3,710 AbbVie shares in Q2 2026, an estimated $807K.
Pathfinder Wealth Consulting first reported a position in AbbVie in Q4 2025 and held it in 2 quarters.
Pathfinder Wealth Consulting's AbbVie position peaked at $958K in Q4 2025.
4,207 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Pathfinder Wealth Consulting's 13F filing for Q2 2026.